Compare Aurobindo Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs GSK PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA GSK PHARMA AUROBINDO PHARMA/
GSK PHARMA
 
P/E (TTM) x 10.7 52.9 20.2% View Chart
P/BV x 2.3 11.1 20.9% View Chart
Dividend Yield % 0.5 1.4 37.8%  

Financials

 AUROBINDO PHARMA   GSK PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
GSK PHARMA
Mar-19
AUROBINDO PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs8093,595 22.5%   
Low Rs5041,253 40.2%   
Sales per share (Unadj.) Rs281.1184.7 152.2%  
Earnings per share (Unadj.) Rs41.426.3 157.3%  
Cash flow per share (Unadj.) Rs50.929.2 174.5%  
Dividends per share (Unadj.) Rs2.5020.00 12.5%  
Dividend yield (eoy) %0.40.8 46.2%  
Book value per share (Unadj.) Rs199.4126.3 157.8%  
Shares outstanding (eoy) m585.88169.40 345.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.313.1 17.8%   
Avg P/E ratio x15.992.2 17.2%  
P/CF ratio (eoy) x12.983.1 15.5%  
Price / Book Value ratio x3.319.2 17.2%  
Dividend payout %6.076.1 7.9%   
Avg Mkt Cap Rs m384,630410,626 93.7%   
No. of employees `00017.35.0 349.4%   
Total wages/salary Rs m21,3085,372 396.7%   
Avg. sales/employee Rs Th9,500.76,306.7 150.6%   
Avg. wages/employee Rs Th1,229.41,083.1 113.5%   
Avg. net profit/employee Rs Th1,397.9898.0 155.7%   
INCOME DATA
Net Sales Rs m164,66631,281 526.4%  
Other income Rs m1,0201,023 99.7%   
Total revenues Rs m165,68632,304 512.9%   
Gross profit Rs m37,7186,009 627.7%  
Depreciation Rs m5,580486 1,148.1%   
Interest Rs m7776 12,953.3%   
Profit before tax Rs m32,3806,540 495.1%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m8,1832,373 344.8%   
Profit after tax Rs m24,2294,454 544.0%  
Gross profit margin %22.919.2 119.2%  
Effective tax rate %25.336.3 69.6%   
Net profit margin %14.714.2 103.3%  
BALANCE SHEET DATA
Current assets Rs m121,87820,061 607.5%   
Current liabilities Rs m86,80614,543 596.9%   
Net working cap to sales %21.317.6 120.7%  
Current ratio x1.41.4 101.8%  
Inventory Days Days13057 228.8%  
Debtors Days Days6814 486.2%  
Net fixed assets Rs m81,03714,343 565.0%   
Share capital Rs m5861,694 34.6%   
"Free" reserves Rs m116,21819,704 589.8%   
Net worth Rs m116,80421,398 545.9%   
Long term debt Rs m4,5122 225,600.0%   
Total assets Rs m211,05239,113 539.6%  
Interest coverage x42.71,091.0 3.9%   
Debt to equity ratio x00 41,329.5%  
Sales to assets ratio x0.80.8 97.6%   
Return on assets %11.811.4 103.9%  
Return on equity %20.720.8 99.7%  
Return on capital %27.431.9 85.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,727534 15,117.5%   
Fx outflow Rs m34,7007,091 489.4%   
Net fx Rs m46,027-6,557 -702.0%   
CASH FLOW
From Operations Rs m19,5483,994 489.5%  
From Investments Rs m-19,570-1,433 1,365.3%  
From Financial Activity Rs m8,642-3,584 -241.1%  
Net Cashflow Rs m8,922-1,023 -872.0%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 8.0 10.2 77.9%  
FIIs % 27.7 23.8 116.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 15.4 66.2%  
Shareholders   69,601 102,036 68.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ORCHID PHARMA LTD  CIPLA  ASTRAZENECA PHARMA  SUVEN LIFESCIENCES  STERLING BIOTECH  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

AUROBINDO PHARMA Surges by 6%; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Oct 14, 2019 | Updated on Oct 14, 2019

AUROBINDO PHARMA share price has surged by 6% and its current market price is Rs 464. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index is AUROBINDO PHARMA (up 5.7%). The top losers are FDC LTD. and DIVIS LABORATORIES (down 0.3%).

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 14, 2019 02:03 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS